Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with ...

Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy - - Follows recently received ...

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...

A naturalized citizen, along with other business leaders, are working to create new resources for undocumented people living ...

Kontoor Brands, Inc. (KTB), the VF-offshoot parent of the Wrangler and Lee brands, has signed a definitive agreement to ...

He can drive a line, legitimately elevate his wingers and break games open when he’s feeling it. He’s capable of being a 90-100 point producer, as evidenced by the 102 points he scored in 2022 ...

This improvement was driven by an incremental EBITDA margin of 44%, well above our target of ... to our balance sheet at an execution of 102.3%. All deals had similar structures to other recent ...

Fantasy baseball breakdowns and insights on Shane McClanahan, Justin Steele, and more as we continue to rank the top starting ...

To limit subjectivity from our power rankings, we’ve put in place a handful of statistical metrics to drive the tiering ...